An observational study in Hypercortisolism and Cushing Syndrome, sponsored by Corcept Therapeutics. Terminated at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2019-07-30.
Sponsored by Corcept Therapeutics · Observational
This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.
This retrospective chart review study seeks to collect data from pediatric patients treated with Korlym (mifepristone) to help provide clinicians with some insight on the potential role of mifepristone in the treatment of pediatric patients with Cushing syndrome.
Only sites that have been identified to have patients appropriate for this protocol will be invited to participate and contribute data on their patients
Data to be collected from a retrospective chart review will include:
Data will be collected for all follow-up visits, up until the most recent encounter prior to IRB approval.
Pediatric patients who have been treated with Korlym for Cushing's syndrome
Exclusion Criteria:
Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym
Drug utilization patterns as assessed by chart review
The retrospective review would analyze the drug utilization patterns of pediatric patients treated with Korlym
Time frame: Length of Korlym therapy, up to 5 years
Weight as assessed by chart review
The retrospective review would analyze changes in Weight (in kg) in pediatric patients treated with Korlym
Time frame: Length of Korlym therapy, up to 5 years
Blood Pressure as assessed by chart review
The retrospective review would analyze changes in Blood Pressure (in mmHg) in pediatric patients treated with Korlym
Time frame: Length of Korlym therapy, up to 5 years
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Corcept Therapeutics